These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 25566730

  • 1. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 2. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L.
    J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
    [Abstract] [Full Text] [Related]

  • 3. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 4. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.
    Rizzoli R, Chapurlat RD, Laroche JM, Krieg MA, Thomas T, Frieling I, Boutroy S, Laib A, Bock O, Felsenberg D.
    Osteoporos Int; 2012 Jan; 23(1):305-15. PubMed ID: 21909729
    [Abstract] [Full Text] [Related]

  • 5. Prior ankle fractures in postmenopausal women are associated with low areal bone mineral density and bone microstructure alterations.
    Biver E, Durosier C, Chevalley T, Herrmann FR, Ferrari S, Rizzoli R.
    Osteoporos Int; 2015 Aug; 26(8):2147-55. PubMed ID: 25851699
    [Abstract] [Full Text] [Related]

  • 6. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N, Bone H, Gilligan JP, Krause DS.
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [Abstract] [Full Text] [Related]

  • 8. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
    Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S.
    J Bone Miner Res; 2010 Dec; 25(12):2558-71. PubMed ID: 20564242
    [Abstract] [Full Text] [Related]

  • 9. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA, Recknor C, Moffett AH, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi-Eis S, Nicholson GC, Muschitz C, Nuti R, Törring O, Wang A, Libanati C.
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [Abstract] [Full Text] [Related]

  • 10. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
    Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK.
    Osteoporos Int; 2011 Jan; 22(1):357-62. PubMed ID: 20458576
    [Abstract] [Full Text] [Related]

  • 11. Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study.
    Zhu TY, Griffith JF, Qin L, Hung VW, Fong TN, Au SK, Tang XL, Kun EW, Kwok AW, Leung PC, Li EK, Tam LS.
    Osteoporos Int; 2015 Jun; 26(6):1759-71. PubMed ID: 25736166
    [Abstract] [Full Text] [Related]

  • 12. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
    Schafer AL, Burghardt AJ, Sellmeyer DE, Palermo L, Shoback DM, Majumdar S, Black DM.
    Osteoporos Int; 2013 Oct; 24(10):2591-601. PubMed ID: 23589163
    [Abstract] [Full Text] [Related]

  • 13. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM, Majumdar S, Brixen K, Chapurlat R, Fuerst T, Engelke K, Dardzinski B, Cabal A, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [Abstract] [Full Text] [Related]

  • 14. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 15. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial.
    Jamal SA, Hamilton CJ, Eastell R, Cummings SR.
    JAMA; 2011 Feb 23; 305(8):800-7. PubMed ID: 21343579
    [Abstract] [Full Text] [Related]

  • 16. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb 23; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 17. Salmon calcitonin in the prevention of bone loss at perimenopause.
    Arnala I, Saastamoinen J, Alhava EM.
    Bone; 1996 Jun 23; 18(6):629-32. PubMed ID: 8806006
    [Abstract] [Full Text] [Related]

  • 18. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L, Kohlmeier L, Kent K, Marcus R.
    J Clin Endocrinol Metab; 1997 Apr 23; 82(4):1111-7. PubMed ID: 9100582
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.
    J Bone Miner Res; 2004 Sep 23; 19(9):1531-8. PubMed ID: 15312255
    [Abstract] [Full Text] [Related]

  • 20. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
    Overgaard K, Lindsay R, Christiansen C.
    Clin Ther; 1995 Sep 23; 17(4):680-5. PubMed ID: 8565031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.